Liberate Bio
Last verified 2026-05-25. JSON
The funding figures on this page are attributed, not sourced: a publisher is on record but no document URL is. How we mark provenance.
| Total raised | $31.0Mattributed |
|---|---|
| Latest round | seed, $31.0M, 2024-06-01attributed |
| Founded | 2022 |
| Headquarters | US |
| Industry | bio |
| Stage | seed |
| Website | liberatebio.com |
Liberate Bio develops genetic medicines using its RAPTOR platform to deliver therapeutic payloads to disease-causing cells that have been hard to reach. It targets patients with blood cancers and autoimmune diseases involving immune cells in blood and marrow. Its delivery tech reaches cell populations once inaccessible to genetic medicines.
Funding rounds
| Date | Round | Amount | Lead |
|---|---|---|---|
| 2024-06-01 | seed | $31.0M | khosla |
Detected tech stack
unknown
Provenance
| Fact | Status | Basis |
|---|---|---|
| Seed, $31.0M | attributed | vc-portfolio named as publisher. No document URL on file. |
| Total raised $31.0M | attributed | vc-portfolio named as publisher. No document URL on file. |
| Company existence | self-reported | liberatebio.com, read 2026-05-25 |
| Description | self-reported | liberatebio.com, read 2026-05-25 |
Nothing on this page is sourced yet. A sourced fact links to a document that states it.
Change history
No change recorded since records began on 2026-09-24.